--- title: "AOD-9604 Dosage Guide [2026] | BodyHackGuide" url: https://www.bodyhackguide.co/guides/dosage/aod-9604 description: "Complete AOD-9604 dosage guide with protocols, calculator, safety info, and where to buy. Updated for 2026." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Metabolic & Weight Loss Phase 2 (discontinued for obesity); research-use-only # AOD-9604 Dosage Guide: Protocols, Calculator & Safety Everything you need to know about AOD-9604 dosing: protocols, safety, and where to buy. Dose Range 250–600 mcg per injection Frequency Once daily, typically morning fasted Cycle Length 12-16 weeks (community-reported; no cycling requirement established, continuous use also reported) Half-Life ~30–60 minutes ## Administration Routes Subcutaneous Oral ### Quick Reconstitution Calculator Calculate syringe units instantly Syringe Draw 10.0 units 2500 mcg/ml · 0.100 ml draw Full Tool (https://www.bodyhackguide.co/tools/reconstitution) For laboratory research use only. This tool performs reconstitution math (concentration and syringe-unit conversion) and is not dosing guidance for humans or animals. ## Dosing Protocols Beginner **Beginner AOD-9604 Protocol — Honest Framing:** **Critical Disclosure First:** Before detailing any protocol, it is essential to state: AOD-9604 failed its pivotal Phase 2B obesity trial. Clinical trial evidence does not support that AOD-9604 produces meaningful weight loss in humans. The protocol below reflects what is commonly done in peptide optimization communities and is provided for informational completeness, not as a recommendation of efficacy. **Typical Starting Protocol:** Format: Subcutaneous injection, daily Dose: 250-300 mcg once daily Timing: Morning, fasted state (30+ minutes before food) Injection site: Abdominal fat (pinch-and-inject technique) Duration: 12-week trial minimum to assess individual response **Reconstitution and Dosing:** - Vial: typically 2 mg or 5 mg lyophilized powder - Reconstitution: add 2 mL bacteriostatic water to 2 mg vial → concentration 1 mg/mL = 1000 mcg/mL - For 250 mcg dose: draw 0.25 mL (25 units on insulin syringe marked 1 mL = 100 units) - For 300 mcg dose: draw 0.30 mL (30 units) - Use 27-30 gauge insulin syringe (U-100 scale) **Injection Technique:** - Swab site with alcohol, allow to dry - Pinch subcutaneous fat (abdomen below umbilicus, or lateral thigh) - Insert needle at 45-90° angle depending on needle length and subcutaneous thickness - Inject slowly over 5-10 seconds - Withdraw needle, apply light pressure with clean cotton/gauze - Dispose of needle in sharps container **Rotation Schedule:** - Alternate abdomen / thigh daily to prevent lipoatrophy - Within abdomen: different quadrants in rotation - Avoid injecting directly into navel area **Storage:** - Lyophilized (unreconstituted): refrigerate, stable for 2+ years - Reconstituted with bacteriostatic water: refrigerate, use within 3-4 weeks - Protect from light - Do not freeze reconstituted solution (affects peptide integrity) **Baseline and Monitoring:** Before starting: - Body weight and composition (DEXA scan if possible, or at minimum tape measurements and photos) - Waist circumference at umbilicus - Body fat percentage (bioelectrical impedance if no DEXA) - Fasting metabolic panel if health relevant - Baseline photos (consistent lighting, pose, time of day) During protocol (every 2-4 weeks): - Weight and circumferences at consistent conditions - Progress photos - Subjective assessment of energy, sleep, appetite, body composition - Notes on concurrent nutrition and training compliance **What to Expect (Realistic):** - Weeks 1-4: no noticeable subjective effects typical; injection routine established - Weeks 4-8: some users report mild subjective changes (appetite, energy) - Weeks 8-12: meaningful objective changes unlikely from AOD-9604 alone; any changes observed likely reflect concurrent nutrition/training changes or placebo response - Honest assessment at 12 weeks: compare before/after metrics; weight loss beyond what diet and exercise alone would achieve is probably not attributable to AOD-9604 **When to Discontinue:** - No measurable objective change at 12 weeks: discontinue, consider evidence-based alternatives - Injection site issues: discontinue - Any unusual symptoms: discontinue, evaluate - Achievement of goal through other interventions: discontinue as unnecessary **Supplementary Essentials (Actually Produce Fat Loss):** - Caloric deficit: 300-500 kcal below maintenance for sustainable fat loss - Protein: 1.2-1.6 g/kg body weight daily to preserve lean mass - Resistance training: 2-3x/week minimum - Sleep: 7-9 hours nightly - Manage stress (cortisol opposes fat loss) These lifestyle factors are the evidence-based foundation; AOD-9604 (if used) is at most an uncertain adjunct. **Cost Consideration:** Research peptide AOD-9604: typically $50-100 per month at 250 mcg daily dose. Over 12 weeks: $150-300. Compare to: - GLP-1 agonists (clinically effective): $100-1000+/month depending on source - Certified personal trainer for resistance training: variable - Sleep tracker and sleep hygiene investment: one-time, high ROI - Nutrition tracking app: free Honest cost-benefit: the $150-300 for a 12-week AOD-9604 trial is likely better invested in a monthly nutritionist consult, quality gym membership, or sleep optimization, given AOD-9604's lack of efficacy evidence. Standard **Intermediate AOD-9604 Protocol — Combination Strategies:** For users who have completed a beginner monotherapy trial and wish to continue exploring AOD-9604 in combination with other interventions, or who are starting directly with a stack approach. **Honest Disclaimer:** AOD-9604 failed its pivotal obesity trial. Any combination protocol derives its real efficacy from the other components; AOD-9604's contribution is speculative. Combinations below are described for informational completeness with honest attribution of what's actually driving results. **Combination 1: GH Axis Optimization** Daily Protocol: - AOD-9604: 300-500 mcg SC in morning fasted state - Ipamorelin: 200-300 mcg SC before bed - CJC-1295 (without DAC): 100 mcg SC before bed - OR: Ipamorelin/CJC-1295 (no-DAC) combined 3x daily (200 mcg Ipamorelin + 100 mcg CJC-1295 per dose) Real mechanism: Ipamorelin is a ghrelin mimetic/GHRP-6 analog that stimulates pulsatile GH release. CJC-1295 (no-DAC) is a short-acting GHRH analog. Together they produce synergistic GH pulses, potentially supporting body composition through IGF-1-mediated effects and direct GH signaling. AOD-9604 adds no independent proven contribution but also no significant additive cost or risk. Expected outcomes (primarily from Ipamorelin/CJC-1295): - Improved sleep quality within 2-4 weeks - Modest fat loss over 12-16 weeks (1-2% body fat) - Lean mass preservation during caloric deficit - Improved recovery from training - IGF-1 rise (monitor with lab testing at 8 weeks) Monitoring: - IGF-1: baseline, 8 weeks, 16 weeks (target 200-300 ng/mL) - Fasting glucose: baseline, 8 weeks (GH can impair glucose tolerance at higher doses) - DEXA body composition: baseline, 12-16 weeks **Combination 2: Comprehensive "Fat Loss" Stack** Daily Protocol: - AOD-9604: 300 mcg SC morning fasted - MOTS-c: 5 mg SC 2-3x weekly - Tesamorelin: 2 mg SC daily (FDA-approved if prescribed; research peptide if sourced outside clinical channels) - Adequate caloric deficit (300-500 kcal below maintenance) - Resistance + cardiovascular training Real mechanism: Tesamorelin has Phase 3 evidence for visceral fat reduction — it's the efficacy driver. MOTS-c has emerging evidence for mitochondrial metabolic effects (less robust data). AOD-9604 is the weakest link mechanistically. Expected outcomes: - Visceral fat reduction measurable on DEXA or abdominal MRI within 12-16 weeks - Attribution: Tesamorelin primary, MOTS-c possibly secondary, AOD-9604 negligible - Standard GH-axis monitoring for Tesamorelin **Combination 3: With GLP-1 Class (Real Weight Loss)** Daily Protocol: - Semaglutide 2.4 mg weekly SC (or tirzepatide 5-15 mg weekly, or oral orforglipron if available) - AOD-9604 250 mcg SC daily (optional adjunct) Real mechanism: GLP-1 agonist is producing 90%+ of the weight loss effect. AOD-9604 contribution is marginal and unproven. Inclusion of AOD-9604 in this protocol is essentially ornamental. Expected outcomes: - Weight loss: 10-20% at 6-12 months (depending on GLP-1 agent and dose) - AOD-9604 attribution: negligible - Consideration: AOD-9604 is adding cost and injection burden without proven benefit; many practitioners would recommend dropping it **Combination 4: Recovery and Body Composition** Protocol: - AOD-9604: 300 mcg SC morning - BPC-157: 250 mcg SC twice daily for acute injury; intermittent for maintenance - TB-500 (Thymosin Beta-4): 2 mg SC twice weekly for injury recovery This stack is oriented toward injury recovery and tissue healing rather than pure fat loss. AOD-9604 is included peripheral to recovery goals. **Combination 5: The "Peptide Skeptic" Approach** Protocol: - Drop AOD-9604 entirely - Focus on Tesamorelin OR Ipamorelin/CJC-1295 for peptide-based body composition support - Use GLP-1 agonist for weight loss if clinically indicated - Emphasize evidence-based lifestyle interventions For many sophisticated users, this simpler approach produces better outcomes than complex stacks that include AOD-9604. **Cycling Considerations:** - AOD-9604: no specific cycling concern; can be used continuously - Ipamorelin/CJC-1295: some users cycle 8 weeks on, 4 weeks off; theoretical basis for HPA axis rest, though not well established - Tesamorelin: continuous use per clinical protocols - GLP-1 agonists: continuous use for weight loss goals **Monitoring Frequency (Intermediate Protocol):** - IGF-1: every 8-12 weeks - Comprehensive metabolic panel: every 3-6 months - HbA1c: every 6 months (if on GH secretagogues with possible glycemic effects) - Body composition: every 12-16 weeks (DEXA ideal) - Symptoms and subjective response: weekly self-assessment **Progressive Optimization:** If results are disappointing at 16-20 weeks: - Evaluate stack for redundancy and cost - Consider dropping AOD-9604 and reallocating resources - Intensify lifestyle interventions (strength training frequency, cardiovascular volume, nutrition precision) - Consider evidence-based medications (GLP-1, Tesamorelin) if not already in protocol - Accept that some genetic body composition targets may not be achievable through peptides alone Advanced **Advanced AOD-9604 Protocol - Expert-Level Considerations:** For highly experienced users, clinicians managing peptide-requesting patients, or those with specific complex scenarios. **Scenario 1: The "I Want to Try AOD-9604 Despite Weak Evidence" Patient** Common patient profile: educated consumer aware that the human obesity program did not confirm efficacy but wants to try AOD-9604 anyway based on anecdotal reports or mechanistic rationale. Approach: - Explicit informed consent regarding the lack of human efficacy evidence - Define clear trial endpoint: 12 weeks at 500 mcg daily as an adequate test of individual response - Objective baseline metrics: DEXA body composition, photos, comprehensive labs - Concurrent optimization: nutrition, training, sleep all controlled/documented - Honest assessment at 12 weeks: compare observed changes to what would be expected from lifestyle interventions alone - Pre-specified discontinuation criteria if no measurable benefit - This approach respects patient autonomy while ensuring they're not wasting resources indefinitely **Scenario 2: Research Peptide Quality Control** Given AOD-9604 is exclusively sourced outside pharmaceutical supply chains for injection, quality varies dramatically. Quality-focused approach: - Source from vendors providing a third-party certificate of analysis (COA) - Verify COA includes: peptide identity (mass spectrometry), purity (HPLC >95%), endotoxin testing (<1 EU/mg), sterility for sterile-filtered product - Reject vendors unwilling or unable to provide a recent COA for the specific lot - Visual inspection on receipt: intact seal, clear vial with no visible particulates, proper labeling - Reconstitute under clean technique; discard if cloudy or with visible contaminants - When switching suppliers, repeat baseline assessment **Scenario 3: Combination With Advanced Body Recomposition Protocols** For bodybuilders or elite athletes pursuing optimized body composition (note: AOD-9604 is prohibited by WADA - see contraindications): Comprehensive Stack (example): - AOD-9604 500 mcg SC daily (fasted morning) - Tesamorelin 2 mg SC daily (evening) - Ipamorelin 300 mcg + CJC-1295 no-DAC 100 mcg SC 3x daily (pulsatile GH) - MOTS-c 5 mg SC 2x weekly - Testosterone optimization (TRT if hypogonadal, or enclomiphene for endogenous support) - HCG 500 IU SC 2x weekly for testicular function preservation (if on TRT) - Creatine monohydrate 5 g oral daily - Protein 2.0-2.2 g/kg lean body mass - Structured 4-5 day strength training - Cardiovascular conditioning 150+ min/week moderate + 2x weekly HIIT - Sleep tracking with 8+ hour target - Caloric cycling: maintenance on training days, 500 kcal deficit on rest days Cost: significant ($500-1500+/month depending on peptide sourcing) Efficacy attribution: - Primary drivers: training, nutrition, testosterone optimization - Secondary: Tesamorelin (for visceral fat), Ipamorelin/CJC-1295 (for GH pulses) - AOD-9604: unclear, possibly ornamental Monitoring: - DEXA: every 12 weeks - Testosterone, free T, estradiol: every 3 months - IGF-1: every 8 weeks - Comprehensive metabolic panel: quarterly - Lipid panel: every 6 months **Scenario 4: Post-Bariatric / Significant Weight Loss Patients** Patients after substantial weight loss (bariatric surgery or GLP-1-mediated) often have residual body composition concerns (loose skin, visceral fat remnants, lean mass preservation needs). Protocol: - Continue primary weight loss intervention as indicated - Add Tesamorelin for residual visceral fat (evidence-based) - Add Ipamorelin/CJC-1295 for GH support - Optional: AOD-9604 500 mcg daily (poor evidence but low risk) - Aggressive protein (2.0+ g/kg lean body mass) - Resistance training as non-negotiable - Realistic skin surgery discussion if skin redundancy is functionally problematic **Scenario 5: Transitioning Patients Off AOD-9604** Patients who have been using AOD-9604 for extended periods and want to discontinue or optimize: Approach: - No taper required (no withdrawal syndrome; no receptor downregulation concerns) - Simply discontinue and redirect resources - Assess what concurrent interventions were providing value - Consider cycling to evidence-based alternatives - No physiological concerns; primary question is psychological transition away from a familiar protocol **Scenario 6: Clinical Practice Considerations** For practitioners (MDs, NPs, PAs) asked about AOD-9604 by patients: Patient education talking points: - Acknowledge patient interest and research - Share that AOD-9604's human obesity program did not confirm efficacy and was discontinued, and that there is no published, peer-reviewed human trial demonstrating weight-loss benefit (be aware that widely circulated citations of a '2008 Heffernan' obesity trial are erroneous - the real Heffernan AOD9604 papers are 2001 rodent studies) - Explain the GRAS determination is a food-safety determination, not efficacy - Note it is prohibited in sport by WADA - Discuss evidence-based alternatives: GLP-1 agonists, Tesamorelin, lifestyle - Respect patient autonomy if they choose to proceed - Document shared decision-making Risk management: - AOD-9604 is not FDA-approved for any indication - Prescribing or recommending it as therapy may expose to professional liability depending on context - Supplement form (oral, low-dose) is legally distinct from compounded or research injectable form - Document informed consent thoroughly **Scenario 7: The Gray Market Peptide Ethics** For patients asking practitioners about research peptide AOD-9604: - Most practitioners cannot prescribe or directly supply research peptides (they're not pharmaceutical products) - Compounding pharmacies may legally compound AOD-9604 with a prescription (limited availability) - Patients sourcing independently online: the practitioner role is harm reduction (injection technique, quality assessment, recognizing adverse events) rather than endorsement - Document discussions clearly **Long-Term Considerations:** - AOD-9604 has been used by individuals for years at various doses without clear safety signals in the peptide community - Absence of evidence is not evidence of absence for long-term risks - Periodic reassessment of cost-benefit: is continuing use producing demonstrable benefit, or just routine? - As the weight loss pharmacology landscape evolves (GLP-1, GIP, glucagon, amylin combinations), AOD-9604's relative position becomes weaker over time **Key Advanced Insight:** The most sophisticated peptide users tend to include AOD-9604 briefly and then move away from it as experience demonstrates other peptides produce more measurable results. If you find yourself in an "AOD-9604 is my core peptide" mindset after 6+ months of use, consider whether you have been pursuing the most impactful interventions. The peptide and obesity pharmacology landscapes have changed dramatically since AOD-9604 was developed in the 1990s. Contemporary options - Semaglutide (https://www.bodyhackguide.co/compound/semaglutide), Tirzepatide (https://www.bodyhackguide.co/compound/tirzepatide), Orforglipron (https://www.bodyhackguide.co/compound/orforglipron), Mazdutide (https://www.bodyhackguide.co/compound/mazdutide), Retatrutide (https://www.bodyhackguide.co/compound/retatrutide), Tesamorelin (https://www.bodyhackguide.co/compound/tesamorelin), Cagrilintide (https://www.bodyhackguide.co/compound/cagrilintide) - provide superior evidence, efficacy, and clinical support for fat loss and body composition goals. ## Weight-Based Dosing Not weight-based. Standard flat doses. ## Commonly Stacked With Because AOD-9604 lacks established efficacy as monotherapy, any stacking strategy should be approached with realistic expectations — AOD-9604 is unlikely to be the efficacy driver in any combination. **Why Users Typically Stack AOD-9604:** In peptide community practice, AOD-9604 is often included in combination protocols because its mechanism is claimed to be non-overlapping with other peptides, its side effect profile is benign, and its "no IGF-1 elevation" property makes it appealing as an adjunct for users already pushing the GH axis with other agents. The belief that AOD-9604 contributes incremental fat loss is the motivating framework, though evidence for this is absent. **Common Stacks and Honest Assessment:** AOD-9604 + Ipamorelin + CJC-1295: - The "GH axis optimization" stack - Real efficacy driver: Ipamorelin + CJC-1295 (raise endogenous GH → body composition effects) - AOD-9604 role: claimed adjunctive lipolysis; unproven - Cost-benefit: adding AOD-9604 to Ipamorelin/CJC-1295 increases cost 30-50% with unclear benefit - See: Ipamorelin (https://www.bodyhackguide.co/compound/ipamorelin), CJC-1295 (https://www.bodyhackguide.co/compound/cjc-1295) AOD-9604 + Tesamorelin: - Redundant axis: Tesamorelin is FDA-approved GHRH analog with Phase 3 efficacy for visceral fat reduction - Tesamorelin raises IGF-1 (slightly); AOD-9604 doesn't - Real efficacy driver: Tesamorelin - See: Tesamorelin (https://www.bodyhackguide.co/compound/tesamorelin) AOD-9604 + MOTS-c: - Claimed synergy: MOTS-c for mitochondrial metabolism + AOD-9604 for lipolysis - MOTS-c has early human data but not large RCTs - Combined efficacy: speculative - See: MOTS-c (https://www.bodyhackguide.co/compound/mots-c) AOD-9604 + 5-Amino-1MQ: - Claimed synergy: 5-Amino-1MQ inhibits NNMT enzyme (hypothesized role in metabolism) + AOD-9604 for lipolysis - Neither compound has robust human efficacy data - See: 5-Amino-1MQ (https://www.bodyhackguide.co/compound/5-amino-1mq) AOD-9604 + GLP-1 Class (Semaglutide, Tirzepatide, Orforglipron): - Real weight loss efficacy comes entirely from the GLP-1 agonist - AOD-9604 contribution: theoretical, unproven, negligible cost-benefit - Most peptide-stack users would be better served by GLP-1 monotherapy at standard doses - See: Semaglutide (https://www.bodyhackguide.co/compound/semaglutide), Tirzepatide (https://www.bodyhackguide.co/compound/tirzepatide), Orforglipron (https://www.bodyhackguide.co/compound/orforglipron) AOD-9604 + BPC-157: - Stacked by users primarily pursuing recovery goals - No mechanistic synergy documented - See: BPC-157 (https://www.bodyhackguide.co/compound/bpc-157) AOD-9604 + Fragmented "Fat Loss Stack" Marketing: - Commercial marketing often bundles AOD-9604 with stimulants (caffeine, yohimbine, synephrine) or thyroid modulators - Real efficacy from stimulant/thermogenic components - AOD-9604 provides a "peptide" veneer for conventional fat burner formulations **What Makes Sense if Using AOD-9604:** For Serious Fat Loss Goals, Prioritize in This Order: 1. Nutrition (caloric deficit, protein, whole foods): always primary 2. Resistance training and cardiovascular exercise: second pillar 3. Sleep optimization: often neglected; profoundly impacts fat loss 4. Validated pharmacotherapy (GLP-1 agonists if clinically indicated): evidence-based 5. Growth hormone axis optimization with evidence-based peptides (Tesamorelin, Ipamorelin/CJC-1295): moderate evidence 6. AOD-9604 if still desired: unlikely to add substantial benefit For Peptide Enthusiasts Committed to Using AOD-9604: - Use at 250-500 mcg SC daily in fasted state (marketed timing recommendation) - Combine with validated peptides rather than as monotherapy - Set realistic expectations: fat loss attribution will be unclear - Monitor body composition (DEXA, circumferences, photos) objectively - Plan a 12-week trial; if no measurable effect beyond what lifestyle changes would produce, discontinue **Red Flag Stacks:** - AOD-9604 + clenbuterol: clenbuterol has cardiovascular risks; AOD-9604 offers no mechanistic complement - AOD-9604 + DNP (dinitrophenol): DNP is dangerous and potentially fatal; no legitimate stack includes it - AOD-9604 + unregulated "thermogenic" stacks from dubious vendors: safety unknown **Key Framing:** AOD-9604 is a low-risk, low-benefit peptide. Stacking can make financial and opportunity-cost sense only if other stack components provide the actual efficacy. If you're stacking to compensate for AOD-9604's lack of monotherapy effect, you've essentially decided to use other peptides — consider whether AOD-9604 is contributing anything or just increasing cost and complexity. ## Side Effects & Safety AOD-9604's side effect profile is largely benign based on available data, reflecting its failure to produce significant physiological effects - a compound that does little tends to cause few side effects. **From the developer's human trials (sponsor-reported; no peer-reviewed RCT published):** Across the doses studied, AOD-9604 was well tolerated: - Injection site reactions: mild, typical for any subcutaneous peptide (mild redness, minor bruising, transient pain) - Headache: occasional - Fatigue: occasional - Minor gastrointestinal symptoms: uncommon - No serious adverse events attributable to AOD-9604 - No clinically significant changes in laboratory parameters - No cardiac rhythm disturbances - No effects on glucose tolerance or insulin sensitivity - No increase in IGF-1 levels (confirming the targeted selectivity) - No adverse effects on thyroid function - No immunogenicity issues (no significant anti-drug antibody formation) **Theoretical Concerns:** - **Peptide immunogenicity**: Any injected peptide carries theoretical risk of immune response; this was not observed in the available AOD-9604 human data - **Purity concerns for research peptide sourcing**: Research-grade peptides sourced outside pharmaceutical supply chains may contain contaminants, incorrect peptide sequences, bacterial endotoxin from synthesis errors, or degraded product. Quality varies substantially across suppliers. - **Injection site complications**: Infection, sterile abscess, or local reactions from improper injection technique or non-sterile reconstitution practices **Oral Supplement Form:** For oral AOD-9604 in supplements (low dose under the GRAS framework): - Reported side effects: minimal to none in marketed use - Likely reason: negligible systemic absorption of the peptide through the oral route - Theoretical concern: any supplement may contain undisclosed adulterants **Compared to Other Peptides:** - AOD-9604 side effect profile is generally milder than: - GLP-1 agonists (nausea, vomiting, GI) - Growth hormone secretagogues (water retention, carpal tunnel, glucose effects at higher doses) - Melanotan-family peptides (nausea, flushing, erections) - This mild profile partly reflects AOD-9604's limited physiological activity **Pregnancy and Lactation:** - Not recommended; insufficient data - No adequate pregnancy studies in humans - Avoid during pregnancy and breastfeeding as standard precaution for any peptide without established safety data **Long-Term Safety:** - Long-term (>6 month) controlled human safety data are not available - Theoretical long-term concerns include immunogenicity with repeated administration over years (not demonstrated in available data) - Effects on cardiovascular outcomes, cancer incidence, or metabolic health over decades are unknown **Contraindications Specific to AOD-9604:** - Prior hypersensitivity to AOD-9604 or peptide components - Known active growth hormone-responsive neoplasms (theoretical caution even though AOD-9604 doesn't activate the GH receptor for growth - conservative practice) - Acute critical illness (analogous to hGH caution, though not mechanistically equivalent) **Who Should Avoid AOD-9604:** - Patients seeking evidence-based weight loss interventions (choose GLP-1 class drugs instead) - Patients with severe adipose-related conditions requiring effective treatment (AOD-9604 is not expected to produce meaningful clinical effects) - Patients on limited budgets (money is better spent on validated interventions) - Patients who have tried AOD-9604 for 12+ weeks without noticeable effect (continuing is unlikely to help) **Harm Reduction for Users Who Proceed:** - Use sterile technique: alcohol swab, fresh needle each injection, bacteriostatic water for reconstitution - Source from reputable vendors with third-party testing / certificates of analysis - Inject subcutaneously in abdominal or thigh fat with a 27-30G insulin syringe - Rotate injection sites to prevent lipoatrophy - Store reconstituted product refrigerated, use within 2-4 weeks - Discontinue if any unusual symptoms develop - Recognize that observed "results" may be largely attributable to concurrent lifestyle changes **Key Honest Framing:** AOD-9604 is not "dangerous" in the typical sense - it has a benign safety profile in the available data. But its primary risk is **opportunity cost**: patients who use AOD-9604 for weight loss and see no results may conclude "peptides don't work for me" or delay seeking evidence-based treatment. For a patient with clinically significant obesity, using AOD-9604 rather than FDA-approved therapies represents a real harm through delayed effective treatment, even if AOD-9604 itself causes no direct adverse effects. Contraindications **Absolute Contraindications:** - Prior serious hypersensitivity to AOD-9604 or peptide excipients - Pregnancy: contraindicated due to inadequate safety data in pregnancy - Active lactation: contraindicated due to inadequate safety data for breastfeeding infants - Pediatric patients under 18: no safety or efficacy data; avoid **Relative Contraindications / Use With Extreme Caution:** - Active malignancy: theoretical concern with any peptide therapy; though AOD-9604 doesn't activate the GH receptor for growth, caution advised until evidence establishes safety in cancer populations - Active critical illness: in ICU populations, growth hormone therapy has paradoxical increased mortality in some studies; AOD-9604's different mechanism may not share this concern, but caution is warranted - Severe immunodeficiency: theoretical injection-site infection risk may be elevated - Active eating disorder (particularly anorexia nervosa or body dysmorphic disorder): marketing AOD-9604 as a fat-loss tool to someone with these conditions risks worsening disordered eating patterns - Severe psychological vulnerability to body image issues: careful screening before prescribing or providing peptide access **Situations Where AOD-9604 Is Inappropriate:** As a substitute for evidence-based obesity treatment: - Patient with clinically significant obesity (BMI >=30 or >=27 with comorbidities) whose primary need is effective weight loss - Patients with prior failure of lifestyle interventions who need pharmacotherapy: choose GLP-1 class drugs over AOD-9604 - Patients with comorbidities that would benefit from effective weight loss: diabetic retinopathy, sleep apnea, osteoarthritis, NASH, cardiovascular disease As a substitute for structured nutrition and exercise: - AOD-9604 is not a replacement for caloric deficit and physical activity - Patients should not delay or substitute lifestyle interventions for peptide therapy **Practitioner / Clinical Considerations:** Regulatory status in your jurisdiction: - Research peptide form: illegal to sell for human use in most jurisdictions; personal possession typically unenforced but legally ambiguous - Oral supplement form: marketed in the US under a self-affirmed GRAS determination; status varies by country - Compounded pharmacy form: may be available with prescription in specific situations Liability exposure: - Prescribing or recommending non-FDA-approved peptides carries professional liability - Document informed consent thoroughly if involved in patient care decisions - Educate patients about evidence-based alternatives before AOD-9604 **Situations Requiring Discontinuation:** Develop during use: - New or worsening injection site complications - Any systemic allergic reaction - Development of pregnancy - Development of diagnosable malignancy - Clinical indication for effective weight loss therapy (switch to evidence-based treatment) Intermittent evaluation: - No objective benefit at 12 weeks: discontinue - Cost-benefit no longer favorable: discontinue - Access to evidence-based alternative becomes available: transition - Achievement of goal through other means: discontinue as unnecessary **Drug Interactions:** No clinically significant drug interactions documented. AOD-9604 does not: - Interact with cytochrome P450 enzymes - Significantly alter absorption of other medications - Compete with other peptide therapies at known receptors - Potentiate or inhibit common prescription drugs Theoretical considerations: - With other injected peptides: additive injection volume and site rotation needs - With anticoagulants: injection site bruising may be more pronounced - With immunosuppressants: injection site infection risk may be slightly elevated **Athletic / Sport-Specific Considerations:** WADA (World Anti-Doping Agency) status: - AOD-9604 is PROHIBITED in sport at all times under WADA Prohibited List class S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). It has been specifically identified as a WADA-banned peptide, and validated urine detection methods for AOD-9604 and its stable metabolite have been published (PubMed 25208511). - Any competitive athlete subject to WADA rules should not use it; the substance is directly covered, and use can result in an anti-doping rule violation. - Detection windows are extended by screening for the stable serum/urine metabolite (CRSVEGSCG). Non-WADA testing (NCAA, professional leagues): - Varies by organization; many follow WADA classifications - Broad peptide panels can detect AOD-9604 or its metabolites **Safety Communication With Patients:** Key points to convey: - AOD-9604's human obesity program did not confirm efficacy and was discontinued - There is no published peer-reviewed human trial showing weight-loss benefit - The GRAS status is about food safety, not drug efficacy - Injectable forms are not FDA-approved and are sold as "research chemicals" - Quality of research peptides varies - It is prohibited in sport by WADA - Evidence-based alternatives exist for weight loss - AOD-9604 is unlikely to cause significant harm but is also unlikely to produce significant weight loss - Decision to use is ultimately about patient autonomy in a context of limited expected benefit - Cost of AOD-9604 may be better allocated elsewhere **Emergency Considerations:** - In case of severe allergic reaction: epinephrine, antihistamines, supportive care - Injection site infection: standard wound care, antibiotics if indicated - Accidental intravascular injection: minimal clinical significance expected with this peptide; monitor - Overdose: no specific toxicity syndrome; supportive care Check interactions with the Interaction Checker → (https://www.bodyhackguide.co/tools/interaction-checker) ## Additional Notes **Dosing Specifications for AOD-9604:** **Injectable (Research Peptide) - The Most Common Form in Practice:** Typical Doses: - Starting/conservative: 250 mcg SC daily - Standard: 300-500 mcg SC daily - Higher-end: 1 mg SC daily (rarely used; not clearly more effective) - Human obesity trials tested a range of subcutaneous doses, including doses well above the community range; efficacy was not confirmed Administration: - Route: Subcutaneous injection - Frequency: Once daily typically; some users split AM/PM (no clear advantage) - Timing: Morning in fasted state (insulin/glucose considerations) - Site: Abdominal fat (preferred) or thigh - Needle: 27-30 gauge insulin syringe - Volume: 0.1-0.5 mL depending on concentration - Duration: Often continuous (but no cycling requirement proven) Vial Sizes and Reconstitution: - Common vial sizes: 2 mg, 5 mg, 10 mg (lyophilized powder) - Reconstitute with bacteriostatic water (contains 0.9% benzyl alcohol as preservative) - Example: 2 mg vial + 2 mL bacteriostatic water = 1 mg/mL concentration - For 500 mcg dose from 1 mg/mL solution: draw 0.5 mL (50 units on U-100 insulin syringe) - For 300 mcg dose from 1 mg/mL: draw 0.3 mL (30 units) Alternative reconstitution: - 5 mg vial + 5 mL bacteriostatic water = 1 mg/mL (same concentration, larger volume for longer use) - 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL (more concentrated, for lower injection volumes) **Oral Supplement Form (Low-Dose):** Under the GRAS framework: - Typical doses: 500 mcg to 5 mg oral - Frequency: Once daily - Absorption: minimal to negligible (peptide structure degraded by gastric proteases) - Expected effect: mechanistically limited - Commercial products: widely varied quality, often combined with other ingredients **Drug Interactions:** Known Interactions: None documented Theoretical Considerations: - With other GH-axis peptides (Tesamorelin, Ipamorelin, CJC-1295, Sermorelin): no pharmacokinetic interaction expected; additive or independent mechanisms - With GLP-1 agonists: no PK interaction; mechanisms non-overlapping - With insulin or anti-diabetic medications: AOD-9604 doesn't alter glucose metabolism, so no expected interaction - With thyroid medications: no interaction documented **Dose Adjustments by Population:** Renal Impairment: - No specific data; peptide small enough that renal clearance is a consideration but no clinical data - Conservative: use standard doses unless severe renal impairment Hepatic Impairment: - No specific data - Conservative: use standard doses Geriatric: - No specific data; use standard doses - Consider lower starting dose with gradual increase Pediatric: - Not recommended; no safety/efficacy data in pediatric populations - Avoid **Storage and Handling:** Lyophilized (unreconstituted): - Refrigerate 2-8 deg C - Protect from light - Shelf life: 2+ years - Do not freeze (some sources suggest this is acceptable; others recommend refrigeration only) Reconstituted (in bacteriostatic water): - Refrigerate 2-8 deg C - Protect from light - Use within 3-4 weeks - Discard if cloudy, discolored, or with visible particulates - Do not freeze **Missed Dose:** - Take next scheduled dose - Do not double dose - Regular compliance matters less with AOD-9604 than with time-sensitive medications **Duration of Use:** - No cycling requirement established - Recommended minimum trial: 12 weeks to assess individual response - Continuous use: no clear upper limit established, but reassess benefit every 3-6 months - Discontinuation: no taper required; no withdrawal syndrome **Research Peptide Quality Variables:** Because AOD-9604 is not pharmaceutical-grade, dose precision depends on: - Vial label accuracy (may not match actual peptide content) - Peptide purity (may be 80-99% pure; impurities affect effective dose) - Reconstitution accuracy (user error in measurement) Practically: a measured "500 mcg dose" from a research peptide vial may deliver 350-500 mcg of actual active peptide depending on quality. This imprecision is accepted by users but should be understood. **Cost Per Dose:** - Research peptide AOD-9604: typically $0.50-$2 per 500 mcg dose - Monthly cost: $15-60 for standard 500 mcg daily - Annual cost: $180-720 - Comparison cost: GLP-1 agonists at $100-1000+/month retail (often covered by insurance for approved indications) **Regulatory Status:** - United States: oral form marketed under a self-affirmed GRAS determination for use in supplements; injectable form is not FDA-approved and is marketed only as a "research chemical" - Canada: no approved status; marketed as research peptide - Europe: no approved status - Australia: developed domestically but never approved; now sold as research peptide - Sport: prohibited by WADA (class S2) - Most countries: legal ambiguity; possession for personal use typically unenforced but commercial distribution requires compliance with local regulations Where to Buy AOD-9604 Compare 5 listings across 4 vendors, from $34.99 https://www.bodyhackguide.co/compound/aod-9604 ## Frequently Asked Questions What is the recommended AOD-9604 dosage? The typical dose range for AOD-9604 is 250–600 mcg per injection. It is usually administered Once daily, typically morning fasted. Always start with the lowest effective dose. How often should I take AOD-9604? Once daily, typically morning fasted Does AOD-9604 need to be cycled? Yes, typical cycle length is 12-16 weeks (community-reported; no cycling requirement established, continuous use also reported). What are AOD-9604 side effects? Where can I buy AOD-9604? Compare 5 listings from 4 vendors on our price comparison page, starting from $34.99. AOD-9604 Full Profile Research data, mechanisms, and pricing https://www.bodyhackguide.co/compound/aod-9604 Interaction Checker Check drug & compound interactions https://www.bodyhackguide.co/tools/interaction-checker ## Related Dosage Guides All Guides (https://www.bodyhackguide.co/guides) ### HGH Fragment 176-191 Metabolic & Weight Loss · Dosage Guide https://www.bodyhackguide.co/guides/dosage/hgh-frag-176-191 ### Retatrutide Metabolic & Weight Loss · Dosage Guide https://www.bodyhackguide.co/guides/dosage/retatrutide ### Semaglutide Metabolic & Weight Loss · Dosage Guide https://www.bodyhackguide.co/guides/dosage/semaglutide ### Tirzepatide Metabolic & Weight Loss · Dosage Guide https://www.bodyhackguide.co/guides/dosage/tirzepatide Free 2026 Peptide Cheat Sheet (PDF) 38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers. Download Free (https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download) Image: BodyHackGuide (https://www.bodyhackguide.co/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide #### Explore - Compare prices: https://www.bodyhackguide.co/compare - Vendors: https://www.bodyhackguide.co/vendors - Deals: https://www.bodyhackguide.co/deals - Coupons: https://www.bodyhackguide.co/coupons - Nootropics: https://www.bodyhackguide.co/nootropics - Brain health: https://www.bodyhackguide.co/brain-health - Blog: https://www.bodyhackguide.co/blog - Guides: https://www.bodyhackguide.co/guides #### Tools - Reconstitution: https://www.bodyhackguide.co/tools/reconstitution - Half-life visualizer: https://www.bodyhackguide.co/tools/halflife - COA reader: https://www.bodyhackguide.co/tools/coa - Cost calculator: https://www.bodyhackguide.co/tools/cost-calculator - Stack builder: https://www.bodyhackguide.co/stack-builder - All tools: https://www.bodyhackguide.co/tools #### Trust & vendors - Vendor directory: https://www.bodyhackguide.co/vendors - Trust scorecard: https://www.bodyhackguide.co/vendors/scorecard - Vendor trust badge: https://www.bodyhackguide.co/vendors/get-vetted - Scoring methodology: https://www.bodyhackguide.co/vendors/methodology - Peptide cheat sheet: https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download #### Company - About: https://www.bodyhackguide.co/about - Affiliate disclosure: https://www.bodyhackguide.co/affiliate-disclosure - Editorial standards: https://www.bodyhackguide.co/editorial-standards - Creators: https://www.bodyhackguide.co/creators - Coaches: https://www.bodyhackguide.co/coaches - 1-on-1 coaching: https://www.bodyhackguide.co/coaching - Privacy: https://www.bodyhackguide.co/privacy - Terms: https://www.bodyhackguide.co/terms - Full site directory: https://www.bodyhackguide.co/site-directory **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology), and we earn a commission from purchases made through some of our links at no extra cost to you. Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · Terms (https://www.bodyhackguide.co/terms) · Privacy (https://www.bodyhackguide.co/privacy) ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Article", "headline": "AOD-9604 Dosage Guide [2026]", "description": "Complete AOD-9604 dosage guide with protocols, calculator, safety info, and where to buy. Updated for 2026.", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/bhglogo.png" } } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is the recommended AOD-9604 dosage?", "acceptedAnswer": { "@type": "Answer", "text": "The typical dose range for AOD-9604 is 250–600 mcg per injection. It is usually administered Once daily, typically morning fasted. Always start with the lowest effective dose." } }, { "@type": "Question", "name": "How often should I take AOD-9604?", "acceptedAnswer": { "@type": "Answer", "text": "Once daily, typically morning fasted" } }, { "@type": "Question", "name": "Does AOD-9604 need to be cycled?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, typical cycle length is 12-16 weeks (community-reported; no cycling requirement established, continuous use also reported)." } }, { "@type": "Question", "name": "What are AOD-9604 side effects?", "acceptedAnswer": { "@type": "Answer", "text": "AOD-9604's side effect profile is largely benign based on available data, reflecting its failure to produce significant physiological effects - a compound that does little tends to cause few side effects.\n\n**From the developer's human trials (sponsor-reported; no peer-reviewed RCT published):**\nAcross the doses studied, AOD-9604 was well tolerated:\n- Injection site reactions: mild, typical for any subcutaneous peptide (mild redness, minor bruising, transient pain)\n- Headache: occasional\n- Fatigue: occasional\n- Minor gastrointestinal symptoms: uncommon\n- No serious adverse events attributable to AOD-9604\n- No clinically significant changes in laboratory parameters\n- No cardiac rhythm disturbances\n- No effects on glucose tolerance or insulin sensitivity\n- No increase in IGF-1 levels (confirming the targeted selectivity)\n- No adverse effects on thyroid function\n- No immunogenicity issues (no significant anti-drug antibody formation)\n\n**Theoretical Concerns:**\n- **Peptide immunogenicity**: Any injected peptide carries theoretical risk of immune response; this was not observed in the available AOD-9604 human data\n- **Purity concerns for research peptide sourcing**: Research-grade peptides sourced outside pharmaceutical supply chains may contain contaminants, incorrect peptide sequences, bacterial endotoxin from synthesis errors, or degraded product. Quality varies substantially across suppliers.\n- **Injection site complications**: Infection, sterile abscess, or local reactions from improper injection technique or non-sterile reconstitution practices\n\n**Oral Supplement Form:**\nFor oral AOD-9604 in supplements (low dose under the GRAS framework):\n- Reported side effects: minimal to none in marketed use\n- Likely reason: negligible systemic absorption of the peptide through the oral route\n- Theoretical concern: any supplement may contain undisclosed adulterants\n\n**Compared to Other Peptides:**\n- AOD-9604 side effect profile is generally milder than:\n - GLP-1 agonists (nausea, vomiting, GI)\n - Growth hormone secretagogues (water retention, carpal tunnel, glucose effects at higher doses)\n - Melanotan-family peptides (nausea, flushing, erections)\n- This mild profile partly reflects AOD-9604's limited physiological activity\n\n**Pregnancy and Lactation:**\n- Not recommended; insufficient data\n- No adequate pregnancy studies in humans\n- Avoid during pregnancy and breastfeeding as standard precaution for any peptide without established safety data\n\n**Long-Term Safety:**\n- Long-term (>6 month) controlled human safety data are not available\n- Theoretical long-term concerns include immunogenicity with repeated administration over years (not demonstrated in available data)\n- Effects on cardiovascular outcomes, cancer incidence, or metabolic health over decades are unknown\n\n**Contraindications Specific to AOD-9604:**\n- Prior hypersensitivity to AOD-9604 or peptide components\n- Known active growth hormone-responsive neoplasms (theoretical caution even though AOD-9604 doesn't activate the GH receptor for growth - conservative practice)\n- Acute critical illness (analogous to hGH caution, though not mechanistically equivalent)\n\n**Who Should Avoid AOD-9604:**\n- Patients seeking evidence-based weight loss interventions (choose GLP-1 class drugs instead)\n- Patients with severe adipose-related conditions requiring effective treatment (AOD-9604 is not expected to produce meaningful clinical effects)\n- Patients on limited budgets (money is better spent on validated interventions)\n- Patients who have tried AOD-9604 for 12+ weeks without noticeable effect (continuing is unlikely to help)\n\n**Harm Reduction for Users Who Proceed:**\n- Use sterile technique: alcohol swab, fresh needle each injection, bacteriostatic water for reconstitution\n- Source from reputable vendors with third-party testing / certificates of analysis\n- Inject subcutaneously in abdominal or thigh fat with a 27-30G insulin syringe\n- Rotate injection sites to prevent lipoatrophy\n- Store reconstituted product refrigerated, use within 2-4 weeks\n- Discontinue if any unusual symptoms develop\n- Recognize that observed \"results\" may be largely attributable to concurrent lifestyle changes\n\n**Key Honest Framing:**\nAOD-9604 is not \"dangerous\" in the typical sense - it has a benign safety profile in the available data. But its primary risk is **opportunity cost**: patients who use AOD-9604 for weight loss and see no results may conclude \"peptides don't work for me\" or delay seeking evidence-based treatment. For a patient with clinically significant obesity, using AOD-9604 rather than FDA-approved therapies represents a real harm through delayed effective treatment, even if AOD-9604 itself causes no direct adverse effects." } }, { "@type": "Question", "name": "Where can I buy AOD-9604?", "acceptedAnswer": { "@type": "Answer", "text": "Compare 5 listings from 4 vendors on our price comparison page, starting from $34.99." } } ] }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Guides", "item": "https://www.bodyhackguide.co/guides" }, { "@type": "ListItem", "position": 3, "name": "Dosage Guides", "item": "https://www.bodyhackguide.co/guides" }, { "@type": "ListItem", "position": 4, "name": "AOD-9604 Dosage", "item": "https://www.bodyhackguide.co/guides/dosage/aod-9604" } ] } ] ```